Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $2.49 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.